Forty Seven

OverviewSuggest Edit

Forty Seven is an immuno-oncology company, which develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities.

StateClosed
TypePublic
Founded2014
HQMenlo Park, US
Websitefortyseveninc.com

Latest Updates

Employees (est.) (Sept 2019)62
Revenue (FY, 2019)$15.7 M
Cybersecurity ratingAMore

Key People/Management at Forty Seven

Mark McCamish

Mark McCamish

President & Chief Executive Officer
Chris H. Takimoto

Chris H. Takimoto

Chief Medical Officer
Ann D. Rhoads

Ann D. Rhoads

CFO
Craig Gibbs

Craig Gibbs

Chief Business Officer
Norman Kruse

Norman Kruse

Chief Patent Counsel
Kyle Elrod

Kyle Elrod

SVP Planning and Operations
Show more

Forty Seven Office Locations

Forty Seven has offices in Menlo Park, Mountain View and Sacramento
Menlo Park, US (HQ)
1490 O'Brien Dr
Mountain View, US
153 Castro St Floor 2
Sacramento, US
400 R St
Show all (3)

Forty Seven Financials and Metrics

Forty Seven Revenue

Forty Seven's revenue was reported to be $15.68 m in FY, 2019
USD

Revenue (FY, 2019)

15.7m

Net income (FY, 2019)

(87.6m)

EBIT (FY, 2019)

(88.5m)

Cash (31-Dec-2019)

213.8m
Annual
USDFY, 2018FY, 2019

Revenue

15.7m

General and administrative expense

15.4m20.4m

R&D expense

56.7m83.8m

Operating expense total

72.1m104.2m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

15.7m

General and administrative expense

3.4m4.4m4.6m5.1m5.0m

R&D expense

13.6m18.0m19.1m18.8m27.1m

Operating expense total

17.0m22.4m23.7m23.9m32.1m
Annual
USDFY, 2018FY, 2019

Cash

10.8m213.8m

Prepaid Expenses

6.8m8.4m

Current Assets

145.9m337.5m

PP&E

1.4m1.2m
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

13.1m23.4m15.5m17.8m31.8m

Prepaid Expenses

3.6m6.6m11.3m11.9m10.6m

Current Assets

61.6m160.6m124.9m110.9m177.3m

PP&E

1.2m1.2m1.2m1.3m1.3m
Annual
USDFY, 2018FY, 2019

Net Income

(70.4m)(87.6m)

Depreciation and Amortization

401.0k523.0k

Accounts Payable

916.0k4.0m

Cash From Operating Activities

(66.0m)(78.1m)
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(31.5m)(53.2m)(23.0m)(46.2m)(61.4m)

Depreciation and Amortization

193.0k289.0k116.0k233.0k386.0k

Accounts Payable

(603.0k)185.0k(808.0k)3.7m(1.5m)

Cash From Operating Activities

(28.1m)(50.9m)(27.3m)(42.7m)(55.9m)
USDQ2, 2018

Financial Leverage

-0.7 x
Show all financial metrics

Forty Seven Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Forty Seven Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Forty Seven Online and Social Media Presence

Embed Graph

Forty Seven News and Updates

SHAREHOLDER ALERT: WeissLaw LLP Investigates Forty Seven, Inc.

NEW YORK, March 3, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Forty Seven, Inc. ("Forty Seven" or the "Company") (NASDAQ: FTSV) in connection with the proposed acquisition of the Company...

Gilead just made a $4.9 billion bet on cancer-drug maker Forty Seven, whose stock skyrocketed 62%

Gilead Sciences on Monday said it plans to buy cancer-drug maker Forty Seven in a $4.9 billion deal. The news sent Forty Seven's stock up as much as 62% during regular trading. The deal is the latest to add to Gilead's presence in cancer immunotherapy, an approach to treating cancer that harnesses…

Gilead to buy drug developer Forty Seven for about $4.9 bln

Gilead Sciences Inc said on Monday it would buy cancer drug developer Forty Seven Inc for $4.9 billion in cash.

Biotech company Forty Seven surges 30% after hours on report of Gilead interest

Shares of cancer-therapy company Forty Seven Inc. shot up more than 30% in after-hours trading Thursday after a report that Gilead Sciences Inc. has made a takeover offer. Bloomberg News reported that Gilead and Forty Seven, a biotech firm that specializes in cancer immunotherapy, are discussing a…

Gilead Sciences Makes Takeover Approach to Forty Seven

Gilead Sciences Makes Takeover Approach to Forty Seven

Forty Seven to Present at Upcoming Investor Conferences in February

MENLO PARK, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced its participation in the following upcoming investor conferences:
Show more

Forty Seven Blogs

Forty Seven, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights

-- Presented Updated Data for Magrolimab Showing Robust, Durable Activity in MDS and AML -- -- Presented Foundational Preclinical Data for FSI-174 and Entered into Collaborations with bluebird bio and Rocket Pharmaceuticals to Expand Development Program -- -- Gilead Acquisition of Forty Seven

Forty Seven and Rocket Pharmaceuticals Announce Research Collaboration for Fanconi Anemia

MENLO PARK, Calif. and NEW YORK , March 11, 2020 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV) and Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) announced today that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty Seven’s novel antibody-based

Gilead to Acquire Forty Seven for $4.9 Billion

Gilead to Acquire Forty Seven for $4.9 Billion Greta.Jankausk… Mon, 03/02/2020 - 06:55 Gilead to Acquire Forty Seven for $4.9 Billion March 2, 2020 at 6:55 AM EST This release is a backfill from a News Wire General – Gilead Gains Fort…

Forty Seven to Present at Upcoming Investor Conferences in March

Forty Seven to Present at Upcoming Investor Conferences in March Content Import Tue, 02/25/2020 - 08:01 Forty Seven to Present at Upcoming Investor Conferences in March February 25, 2020 at 8:00 AM EST This release is a backfill from a News Wire …

Forty Seven, Inc. Announces Updated Data from Ongoing Clinical Trial of Magrolimab Showing Robust, Durable Activity in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

-- CR Rate of 50% and ORR of 92% Observed in Untreated Patients with Higher-Risk MDS -- -- CR/ CRi Rate of 55% and ORR of 64% Observed in Patients with Untreated AML Who are Ineligible for Induction Chemotherapy -- -- Median Duration of Response Not Yet Reached, with Patients on Treatment for More

bluebird bio and Forty Seven Announce a Research Collaboration to Study an All Antibody Conditioning Regimen for Use in Combination with Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy

November 12, 2019 07:00 AM Eastern Standard Time CAMBRIDGE, Mass. & MENLO PARK, Calif.--( BUSINESS WIRE )-- bluebird bio, Inc.  (Nasdaq: BLUE) and  Forty Seven, Inc.  (Nasdaq:FTSV) announced today that they have entered into a research collaboration to pursue clinical proof-of-concept for Forty
Show more

Forty Seven Frequently Asked Questions

  • When was Forty Seven founded?

    Forty Seven was founded in 2014.

  • Who are Forty Seven key executives?

    Forty Seven's key executives are Mark McCamish, Chris H. Takimoto and Ann D. Rhoads.

  • How many employees does Forty Seven have?

    Forty Seven has 62 employees.

  • What is Forty Seven revenue?

    Latest Forty Seven annual revenue is $15.7 m.

  • What is Forty Seven revenue per employee?

    Latest Forty Seven revenue per employee is $252.9 k.

  • Who are Forty Seven competitors?

    Competitors of Forty Seven include Immunicom, JW Therapeutics and Advanced Cancer Therapeutics.

  • Where is Forty Seven headquarters?

    Forty Seven headquarters is located at 1490 O'Brien Dr, Menlo Park.

  • Where are Forty Seven offices?

    Forty Seven has offices in Menlo Park, Mountain View and Sacramento.

  • How many offices does Forty Seven have?

    Forty Seven has 3 offices.